Do you know any product segment, where one does not get to encounter Chinese products? Well, hardly any. It has been the focus of Chinese government for the past several decades to dominate various industrial sectors, including pharmaceuticals. While, China has been the big production factory for generic drugs and API ingredients for many years, more and more discovery projects have now started going through China. This includes clinical development as well.

In fact, Chinese government has brought regulatory reforms recently that shakes up the global pharmaceutical R&D sector immensely. Read our previous article on Chinese regulatory reforms pertaining to the clinical research and pharmaceutical product registrations.

Challenges with Chinese regulatory reforms

This regulatory reforms seem to create a friendly environment for pharmaceutical development and market access and might prove to catalysts for growth not just in China, but worldwide. However, there are some uncertainties and challenges faced by market leaders.

The practical challenges for Global pharmaceutical companies are

  • Transparency, communication and understanding the new regulatory system,
  • Incorporating China in global simultaneous development,
  • ICH guidelines integration,
  • Adapting innovative standards for new technologies for innovative drug development,
  • Drug life cycle management, e.g. drug withdrawal system building are still encountered
  • along with language and cultural differences issues.

Various factors like

  1. Concurrent use of both western and Chinese medicines,
  2. Pharmacogenetic variances,
  3. Lack of multidisciplinary team,
  4. Impact on disease management and
  5. Drug safety monitoring

are having an impact on drug development in China

In our earlier blog, ”Changing Clinical Trials Scenario In China” we talked about the changing regulatory policies in the last few years, with key highlights being acceptance of data from overseas trials and reduction of the regulatory approval timelines.

But, practically, how this is evolving, will make a lot of difference.

Many pharma / CRO / regulatory consultant believe that it will take a while for the complete transformation to take place.

Recent interactions with experts on the matter tells a different story. Let’s talk about that in a minute, after understanding the current changes and regulatory timelines.

Current Clinical Trial Approval Process in China

Let’s have a look at the best scenario and timelines associated with IND application in China.

 

Key features of this timeline.

  • IND Review timelines has reduced to 60 working days, along with simplified process.
  • If no queries are raised by CDE, IND application is considered to be approved.
  • In the best case scenario, Study start up timelines has been reduced to 11-13 months for IND application, which includes Dossier preparation, pre-IND meeting and application, EC and OHGRA approval and contract finalization to enrolling the first patient in the trial.

Practical problems and questions

Now, coming back to the practical implications on applicant’s experience, some significant steps, like

  • pre-IND meeting
  • OHGRAC approval

can be the road-blocks, if not handled properly.

Many questions arise about a smooth process there.

  1. Are the timelines being followed? Has anyone got approval within these timelines?
  2. How much data/information is sufficient for IND dossier submission?
  3. How much data needs to be given to regulators for pre IND meetings for the best meeting output?
  4. How to engage NMPA assessors during pre-IND to have a meaningful application?
  5. How to work along with the existing reforms without jeopardizing the speed and regulatory compliance of development projects?

Practical steps to have a successful Chinese clinical trial application process

In recent DIA China 2019 event, where many prominent professionals shared their experience with new regulations and NMPA, it was clear that there is a way for all applicants to have a smooth way through the application process.

1. The key is in the clarity!

Lack of clarity of these reforms and regulations can cost the delay in approval and increased R&D cost for the companies. At the same time, a thoroughly defined clinical development strategy of their product is a must to face the regulators.

Are you planning to file a regulatory application for your product and unclear about regulations and process to follow?

Get in touch with us today

Provide your preliminary details about the product application and your details to get started

Provide brief info on your product and registration requirements.
Provide your work email, where we can contact you

2. Communication, communication and communication!

Communicating effectively with regulators at critical milestones can give the sponsor the opportunity to jointly solve difficult problems and issues which are not covered by technical guidelines.

Three types of Meeting request suggested by Administrative Provisions for Communication about Pharmaceutical Research & Development and Technical Review in June 2016.

 

Communication with CDE during the Pre-IND and Pre-NDA meetings are usually conducted in face to face meeting. Applicant can also have a chance to communicate via phone or email during the review process

Problems faced in communications

Common problems faced while communicating with regulatory are

  1. Preparation of information – how much is data sufficient?
    • Provide sufficient background information to support the product in question, but not equivalent to ND submissions
    • Provide sufficient information to support the issues discussed, including the original text of the document which is clear, hierarchical, and detailed
    • Submit a conference communication slide Conducive to reviewers to improve efficiency
  2. Way of asking a question – How to ask questions?
    • Problem should be specific.
    • There should be a solid support for the proposed communication problem, which can be judged by the management department
    • Avoid asking very broad or open questions.
  3. Communication process
    • Applicants should have a process of self-analysis and evaluation of the proposed communication questions – not just the results of the research and the list of references
    • There should be a preliminary answer to the questions raised. Discussion based on science and realistic operability
    • For all meetings with regulatory body, meeting application materials should be submitted within the specified time period, and they grants and arranges meetings, provided they receive appropriate information to support the discussion and sufficient time for review and discussion. If you fail to submit in time, the meeting application may be cancelled.
  4. Communicating minutes of meeting
    • Final Minutes of meeting should be communicated to the management team

Tips for effective communication

For improvising the quality of communication, regulatory authorities and sponsor need to continuously follow an effective set of rules, applied in a timely and consistent manner.

  • A mutual understanding of the terms and phrases used in communication: use of them by both parties is consistent
  • Legal or words to depict rules must be clearly distinguishable from words that are used for suggestions or nice-to-have issues.
  • Because of the different cultures, communication styles, preferences, and documentation needs, there is no “one line” of best communication methods and a continuous improvement must be targeted.
  • For time-critical matters, the telephone communication between the sponsor and the FDA project manager may be relatively more effective than the E-mail.
  • The best practice is to follow up with the written communications after the telephonic conversation to document the decisions made during the contact period, and to agree on the action items.

Conclusion

While, the recent reforms in chinese regulatory process for clinical trial application as well as product approval process appear overwhelming, there is a clear way possible to make it effective. It’s certainly not a straightforward or short term process, but more of forming a habit of effective dealing with Chinese authorities. It’s important to
Gain experience in submitting to NMPA and thus, achieve expertise; or
Hire an expert who has experience in dealing with your projects and who can deliver.

Are you planning to file a regulatory application for your product and unclear about your strategic partner?

Talk to us today

Provide your preliminary details about the product application and your details to get started

Provide brief info on your product and registration requirements.
Provide your work email, where we can contact you

 

It’s possible to have a successful and effective approval performed without compromising your project plans. Need is to be proactive and a great communicator.

 

Reference

  1. https://www.pharmaceuticalonline.com/doc/an-analysis-of-regulatory-reforms-in-china-s-pharmaceutical-market-0001
  2. https://cdn.ymaws.com/www.casss.org/resource/resmgr/wcbp_speaker_slides/2018_WCBP_LiMin.pdf
  3. https://cdn.ymaws.com/www.casss.org/resource/resmgr/cmc_japan/2018_CMCJP_MengYang.pdf
  4. https://www.pharmasug.org/proceedings/2019/SS/PharmaSUG-2019-SS-014.pdf
  5. https://www.lionbridge.com/blog/life-sciences/chinese-pharma-regulatory-changes-3-implications-for-the-world
  6. https://www.researchgate.net/publication/309689086_Challenges_for_drug_discovery_and_development_in_China
  7. https://www.researchgate.net/publication/315631213_Obstacles_and_opportunities_in_Chinese_pharmaceutical_innovation